Cancer Cell Reprogramming and Emerging Approaches
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Cell Biology and Tissue Engineering".
Deadline for manuscript submissions: closed (22 April 2024) | Viewed by 143
Special Issue Editors
Interests: neurological disorders; cancer metabolism; genetics; heredity toxicology biochemistry; molecular biology cell biology
Interests: basic mechanism of alcohol-induced liver injury; neutrophils in ALD pathogenesis
Special Issue Information
Dear Colleagues,
Since the concept of cellular plasticity was established, remarkable progress has been made in reprogramming terminally differentiated somatic cells and cancer cells into induced pluripotent cells and cancer cells with benign phenotypes. Cancer cell reprogramming has emerged as a promising strategy which can induce the transition from malignancy to benignity. A number of intra- and extracellular factors are already described to be implicated in cancer cell reprogramming, such as epigenetic factors, genetic mutations, intracellular pro-malignant, and pro-survival signaling pathways, etc. Additionally, a variety of microenvironmental factors play a critical role in the formation of carcinoma cells of different aggressiveness and sensitivities to currently used therapeutic approaches. Thus, it is proposed that hypoxia and non-malignant cells comprising the tumor such as stroma cells and immune cells could also modify the physiological and molecular properties of carcinoma cells and affect their sensitivities to treatment.
In the past decade, increasing studies have explored various approaches to induce reprogramming from one cell type to another, including lineage-specific transcription factors-, combinatorial small molecules-, microRNAs-, metabolism- and embryonic microenvironment-derived exosome-mediated reprogramming. Much effort has been focused on optimizing reprogramming protocols and deciphering molecular mechanisms to achieve high efficiency, safety, and specificity. The rapid evolution of cancer cell reprogramming has provided substantial insights into biomedical science and translational medicine.
The aim of this Special Issue is to highlight the variety of factors associated with cancer cell reprogramming and the recent approaches to facilitating reprogramming therapy for in vitro/in vivo cancer transition.
Dr. Yan Ma
Dr. Jing Ma
Dr. Sanjay Mukherjee
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
